Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06334432 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
A Phase 1 study of Pancreatic Cancer and Advanced Solid Tumor, sponsored by Nuvation Bio.
- Active
- Registry status
- Phase 1
- Development phase
- 466
- Enrollment target
- 8
- Study locations
NCT06334432: Active Phase 1 study of Pancreatic Cancer and Advanced Solid Tumor, sponsored by Nuvation Bio.
NCT06334432 is a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Nuvation Bio. The registered enrollment target is 466 participants, above the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (19% higher). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06334432, a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Nuvation Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 466 participants
- Enrollment target
- 8
- Study locations
Study Summary
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Primary Outcome
Number of patients with dose limiting toxicities, treatment emergent adverse events (TEAE) and serious adverse events (SAE) and laboratory abnormalities
Conditions Studied
Interventions
- DRUG NUV-1511
Study Locations (8)
Michigan
- Karmanos Cancer Center - Detroit
New Jersey
- Hackensack University Medical Center - Hackensack
New York
- Memorial Sloan-Kettering Cancer Center - New York
North Carolina
- Carolina BioOncology Institute - Huntersville
Texas
- NEXT Oncology - Irving
Utah
- START Mountain - Salt Lake City
Virginia
- NEXT Oncology - Fairfax
Washington
- Fred Hutchinson - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2024-03-14 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What the registry record for NCT06334432 still lists
NCT06334432 is an interventional study that assigns participants to a tested intervention. The registered 466 participants enrollment target is mid-sized for trials with a published cap, above the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (19% higher).
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which NUV-1511 is the first listed.
NCT06334432 lists 8 locations in 8 states (Michigan, New Jersey, New York).
Frequently Asked Questions
What is clinical trial NCT06334432 about?
NCT06334432 is a clinical study titled "Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors". NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase ...
What is the current status of trial NCT06334432?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 466 participants. The study started on 2024-03-14. Estimated completion is 2027-10.
What conditions does trial NCT06334432 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Solid Tumor, HER2-Negative Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Platinum-resistant Ovarian Cancer (PROC).
What interventions are being tested in trial NCT06334432?
The interventions under investigation include: NUV-1511 (DRUG).
Who is sponsoring clinical trial NCT06334432?
This trial is sponsored by Nuvation Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06334432 being conducted?
This trial has 8 study locations across Michigan, New Jersey, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06334432's enrollment target sits among peer trials
466 34th of 278 higher than 245 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
- NCT07055165 · 466 participants · NA
Connect2Care: Prostate Cancer Education and Screenings for African American Men
- NCT07214779 · 466 participants · Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI